Three-Year Retention Rates of Levetiracetam, Topiramate, and Oxcarbazepine: A Retrospective Hospital-Based Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sunwoo, Jun-Sang | - |
dc.contributor.author | Park, Byeong-Su | - |
dc.contributor.author | Ahn, Seon Jae | - |
dc.contributor.author | Hwang, Sungeun | - |
dc.contributor.author | Park, Chan-Young | - |
dc.contributor.author | Jun, Jin-Sun | - |
dc.contributor.author | Kim, Dong Wook | - |
dc.contributor.author | Lee, Soon-Tae | - |
dc.contributor.author | Jung, Keun-Hwa | - |
dc.contributor.author | Park, Kyung-Il | - |
dc.contributor.author | Chu, Kon | - |
dc.contributor.author | Jung, Ki-Young | - |
dc.contributor.author | Lee, Sang Kun | - |
dc.date.accessioned | 2021-08-11T15:24:15Z | - |
dc.date.available | 2021-08-11T15:24:15Z | - |
dc.date.issued | 2017-03 | - |
dc.identifier.issn | 0362-5664 | - |
dc.identifier.issn | 1537-162X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7741 | - |
dc.description.abstract | Objectives: We evaluated and compared the 3-year retention rates of levetiracetam (LEV), topiramate (TPM), and oxcarbazepine (OXC) in patients with epilepsy in routine clinical practice. Methods: We retrospectively reviewed medical records of patients with epilepsy who were newly prescribed LEV, TPM, or OXC from 2006 to 2010. The retention rates were estimated by the Kaplan-Meier analysis, and independent risk factors for drug discontinuation were analyzed by the Cox regression method. Results: A total of 588 patients were included: LEV (n = 345), TPM (n = 190), and OXC (n = 53). Among them, 82% had focal epilepsy, whereas 14.8% had generalized epilepsy. The 3-year retention rates for LEV, TPM, and OXC, were 81.2%, 78.3%, and 54.7%, respectively. Levetiracetam and TPM had equivalent retention rates, whereas patients remained on OXC for a significantly shorter amount of time (P < 0.001). A lower retention rate for OXC was also evident in the subgroup analysis of focal epilepsy (P < 0.001). In generalized epilepsy, LEV and TPM revealed comparable retention rates (P = 0.255). The seizure-freedom rate did not differ among groups, whereas the rate of adverse effects leading to drug withdrawal of OXC (87.5%) was higher than that of LEV (34.4%, P < 0.001) and TPM (52.5%, P = 0.012). Conclusions: The current study suggested that LEV and TPM had comparable retention profiles in the long-term treatment for both focal and generalized epilepsy. Meanwhile, OXC therapy seemed to be relatively less useful because of its poor tolerability. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Lippincott Williams & Wilkins Ltd. | - |
dc.title | Three-Year Retention Rates of Levetiracetam, Topiramate, and Oxcarbazepine: A Retrospective Hospital-Based Study | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1097/WNF.0000000000000204 | - |
dc.identifier.scopusid | 2-s2.0-85010904505 | - |
dc.identifier.wosid | 000397829400002 | - |
dc.identifier.bibliographicCitation | Clinical Neuropharmacology, v.40, no.2, pp 56 - 62 | - |
dc.citation.title | Clinical Neuropharmacology | - |
dc.citation.volume | 40 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 56 | - |
dc.citation.endPage | 62 | - |
dc.type.docType | Review | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | LONG-TERM RETENTION | - |
dc.subject.keywordPlus | ANTIEPILEPTIC DRUGS | - |
dc.subject.keywordPlus | CLINICAL-PRACTICE | - |
dc.subject.keywordPlus | REFRACTORY EPILEPSY | - |
dc.subject.keywordPlus | TOLERABILITY | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | ADULTS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | PROFILE | - |
dc.subject.keywordAuthor | antiepileptic drug | - |
dc.subject.keywordAuthor | levetiracetam | - |
dc.subject.keywordAuthor | oxcarbazepine | - |
dc.subject.keywordAuthor | retention rate | - |
dc.subject.keywordAuthor | topiramate | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.